As a privately owned genomics company based in Ann Arbor, Michigan, Everist Genomics designs advanced products that can improve the treatment outcome for a wide range of severe medical conditions including cancer.
Online PR News – 01-June-2011 – – As a privately owned genomics company based in Ann Arbor, Michigan, Everist Genomics designs advanced products that can improve the treatment outcome for a wide range of severe medical conditions including cancer, cardiovascular disease, neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, and diabetes. As a part of their business strategy, they have a well-established network of partnerships as well as collaboration with some of the world’s leading research centers and internationally renowned like The University of Michigan School of Public Health, Sanford Health’s BioBank, The University of Michigan's Department of Pathology, The University of Southern California Department of Pathology, Mayo Validation Support Services, and The Netherlands Organization for Applied Scientific Research.
The company does research with established doctors in the field of oncology and diagnostics testing such as Professor Stephen B. Gruber (M.D., Ph.D., and M.P.H.). The company’s main areas of focus include proprietary research and development, innovative prognostics that have a substantial impact medically and financially, in-licensing, and targeted acquisitions. Following this business model, the company has been able to successfully create significant technological advancements such as their proprietary Evolver platform which drastically improves the launch rate of advanced molecular prognostic tests.
Only recently the company has received wide recognition for developing the colorectal cancer prognostic test OncoDefender™-CRC which helps medical practitioners make critical decisions for post-surgery treatment of Stage I rectal cancer and Stage I/II colon cancer. Another success story is AngioDefender which is a result of their majority interest in Angiologix Inc.. This device is a tester that can detect early damage to endothelial cells even in asymptomatic patients who do not exhibit abnormal blood pressure and cholesterol levels. This makes it possible for doctors to recommend early treatment which can significantly improve the chances of at-risk patients. Additionally the company has a program wherein patients with no insurance can avail of a variety of financial assistance programs for up to 80% of diagnostic testing fees, patients can visit Everistgenomics.com for more information.